Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.

Human gene therapy - 10 Sept 1996

Ko S C, Gotoh A, Thalmann G N, Zhau H E, Johnston D A, Zhang W W, Kao C, Chung L W

Abstract excerpt

The lethal phenotypes of advanced prostate cancer are androgen independent (AI) and metastatic to the axial skeleton. Our laboratory has developed an AI mouse model of metastatic human prostate cancer. In this communication, we report the development of tumor suppressor gene therapy in this AI and metastatic (C4-2) cancer model. By using recombinant adenovirus as a delivery vehicle, we introduced a wild-type p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Division
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, p53

Share to Genetic Vectors

Share to Mice, Nude

Share to Mutation

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 8886839
DOI: 10.1089/hum.1996.7.14-1683

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.PMID 8886839Read ↗

Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.Semantic proximity Read ↗

Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.Semantic proximity Read ↗

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectivesSemantic proximity Read ↗

Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.Semantic proximity Read ↗

Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus.Semantic proximity Read ↗

Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene.Semantic proximity Read ↗

Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein.Semantic proximity Read ↗

Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer.Semantic proximity Read ↗

Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes.Semantic proximity Read ↗

Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.Semantic proximity Read ↗

Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model.Semantic proximity Read ↗

Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.